A novel molecular classification method for osteosarcoma based on tumor cell differentiation trajectories

Subclassification of tumors based on molecular features may facilitate therapeutic choice and increase the response rate of cancer patients. However, the highly complex cell origin involved in osteosarcoma (OS) limits the utility of traditional bulk RNA sequencing for OS subclassification. Single-ce...

Full description

Saved in:
Bibliographic Details
Published in:Bone Research 2023-01, Vol.11 (1), p.1-1
Main Authors: Zhang, Hao, Wang, Ting, Gong, Haiyi, Jiang, Runyi, Zhou, Wang, Sun, Haitao, Huang, Runzhi, Wang, Yao, Wu, Zhipeng, Xu, Wei, Li, Zhenxi, Huang, Quan, Cai, Xiaopan, Lin, Zaijun, Hu, Jinbo, Jia, Qi, Ye, Chen, Wei, Haifeng, Xiao, Jianru
Format: Article
Language:English
Subjects:
Bone cancer
Sarcoma
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Subclassification of tumors based on molecular features may facilitate therapeutic choice and increase the response rate of cancer patients. However, the highly complex cell origin involved in osteosarcoma (OS) limits the utility of traditional bulk RNA sequencing for OS subclassification. Single-cell RNA sequencing (scRNA-seq) holds great promise for identifying cell heterogeneity. However, this technique has rarely been used in the study of tumor subclassification. By analyzing scRNA-seq data for six conventional OS and nine cancellous bone (CB) samples, we identified 29 clusters in OS and CB samples and discovered three differentiation trajectories from the cancer stem cell (CSC)-like subset, which allowed us to classify OS samples into three groups. The classification model was further examined using the TARGET dataset. Each subgroup of OS had different prognoses and possible drug sensitivities, and OS cells in the three differentiation branches showed distinct interactions with other clusters in the OS microenvironment. In addition, we verified the classification model through IHC staining in 138 OS samples, revealing a worse prognosis for Group B patients. Furthermore, we describe the novel transcriptional program of CSCs and highlight the activation of EZH2 in CSCs of OS. These findings provide a novel subclassification method based on scRNA-seq and shed new light on the molecular features of CSCs in OS and may serve as valuable references for precision treatment for and therapeutic development in OS.
ISSN:2095-4700
2095-6231
DOI:10.1038/s41413-022-00233-w